InDex and Parexel to Collaborate in Phase 2b CONDUCT Study of Kappaproct for UC

InDex and Parexel to Collaborate in Phase 2b CONDUCT Study of Kappaproct for UC
InDex Pharmaceuticals and the contract research organization (CRO) Parexel are partnering to manage the overseas Phase 2b CONDUCT dose optimization clinical trial of Kappaproct (cobitolimod) for the treatment of moderate to severe active ulcerative colitis (UC). Based on the contract between the companies, the first patient in the CONDUCT study will be enrolled during the second quarter of

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *